skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: {sup 225}Ac/{sup 213}Bi biomedical generator

Journal Article · · Transactions of the American Nuclear Society
OSTI ID:552686
; ;  [1]
  1. Oak Ridge National Lab., TN (United States); and others

Among the very limited number of potential alpha emitters, {sup 213}Bi has recently entered phase I of human trial against lung tumor in mice has shown total eradication of implanted tumors. Bismuth-213 decays with a t{sup {1/2}} of 45.6 min and emits an 8.4-MeV alpha particle 97.8% of the time. The decay of {sup 213}Bi follows with the emission of rather low abundance gamma rays: 440 keV (16.5%) and 1566 keV (2%). Carrier-free {sup 213}Bi is available from the {sup 225}Ac/{sup 213}Bi generator system with {sup 225}Ac (t{sub {1/2}} = 10 days) being the daughter of 7340-yr {sup 229}Th, which, in turn, is the decay daughter of long-lived {sup 233}U. Uranium-233 was produced at Oak Ridge National Laboratory (ORNL) in the 1960s and 1970s as part of the molten salt breeder reactor program. Thorium-229 was separated from a waste stream of {sup 233}U processing that had been stored in a number of waste tanks at ORNL. Our current inventory is {approximately}65 mCi of low-specific-activity ({approximately}0.4%) {sup 229}Th.

OSTI ID:
552686
Report Number(s):
CONF-971125-; ISSN 0003-018X; TRN: 98:001892
Journal Information:
Transactions of the American Nuclear Society, Vol. 77; Conference: 1997 American Nuclear Society (ANS) winter meeting, Albuquerque, NM (United States), 16-20 Nov 1997; Other Information: PBD: 1997
Country of Publication:
United States
Language:
English